Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Nutra Pharma Corp. (OTC: NPHC).

Full DD Report for NPHC

You must become a subscriber to view this report.


Recent News from (OTC: NPHC)

Nutra Pharma Comments on SEC Complaint
Nutra Pharma is providing comments on the SEC Complaint filed against Nutra Pharma, its CEO and a Consultant to the company. CORAL SPRINGS, Fla., Sept. 28, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Nutra Pharma Corporation (OTC: NPHC), provided the following comment on the lawsuit fi...
Source: GlobeNewswire
Date: September, 28 2018 17:58
Nutra Pharma announces updates with EuroAmerican IP & BioArmor, LLC, a Service-Disabled Veteran-Owned Small Business for Sales through GoVets.com
CORAL SPRINGS, Fla., Sept. 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin ® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that their wo...
Source: GlobeNewswire
Date: September, 25 2018 08:30
Nutra Pharma Announces Agreement to Launch Comprehensive Internet Marketing Campaign
Nutra Pharma is announcing its agreement with an Internet marketing firm for their Over-the-Counter Pain Remedies: Nyloxin® and Pet Pain-Away™ CORAL SPRINGS, Fla., July 17, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Nutra Pharma Corporation (OTC:NPHC), a biotechnology com...
Source: GlobeNewswire
Date: July, 17 2018 08:30
Nutra Pharma Announces Direct Mail Campaign for Pet Pain-Away(TM) Private Label Brand
Nutra Pharma is announcing the next phase of marketing their Over-the-Counter (OTC) pain reliever for dogs and cats, Pet Pain-Away ™ through their direct response partner, DEG Productions CORAL SPRINGS, Fla., July 03, 2018 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC:NPH...
Source: GlobeNewswire
Date: July, 03 2018 08:30
Nutra Pharma Signs Definitive Letter of Intent for $4 Million Joint Venture Financing
Nutra Pharma is announcing the execution of a Letter of Intent for a $4 Million financing to fund a joint venture for the marketing and distribution of the Company’s Over-the-Counter products. CORAL SPRINGS, Fla., June 28, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Nutra Pharm...
Source: GlobeNewswire
Date: June, 28 2018 08:30
Nutra Pharma Announces Direct Response Television Campaign for Pet Pain-Away(TM)
Nutra Pharma is announcing the next phase of marketing their Over-the-Counter (OTC) pain reliever for dogs and cats, Pet Pain-Away ™ through their direct response partner, DEG Productions. CORAL SPRINGS, Fla., June 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Nutra Pha...
Source: GlobeNewswire
Date: June, 06 2018 08:30
Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution
CORAL SPRINGS, Fla., April 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that they have partnered...
Source: GlobeNewswire
Date: April, 19 2018 08:30
Nutra Pharma Files Provisional Patent for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
CORAL SPRINGS, Fla., April 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin ® and Pet Pain-Away ™ in the over-the-counter (OTC) pain management market, and which is also developing treatments fo...
Source: GlobeNewswire
Date: April, 10 2018 08:30
Nutra Pharma Announces Corporate Updates
CORAL SPRINGS, Fla., March 08, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis (MS) and HIV and that also markets the over-the-counter (OTC) pain drugs; Nyloxin® and ...
Source: GlobeNewswire
Date: March, 08 2018 08:30
Nutra Pharma Files Provisional Patent for Nerve Agent Counter Measures
CORAL SPRINGS, Fla., Feb. 21, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin ® and Pet Pain-Away ™ in the over-the-counter (OTC) pain management market, and which is also developing treatments fo...
Source: GlobeNewswire
Date: February, 21 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.00050.00040.00050.00041,651,521
2018-12-170.00030.00040.00040.00034,962,750
2018-12-140.00040.00040.00040.0003522,614
2018-12-130.00040.00040.00040.00034,132,936
2018-12-120.00030.00040.00040.00038,192,818

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-181,650,8501,651,52199.9594Short
2018-12-171,240,0004,962,75024.9861Cover
2018-12-1466,687520,31412.8167Cover
2018-12-132,991,3134,132,93672.3774Short
2018-12-121,907,8108,192,81823.2864Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NPHC.


About Nutra Pharma Corp. (OTC: NPHC)

Logo for Nutra Pharma Corp. (OTC: NPHC)

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis MS , Human Immunodeficiency Virus HIV , Adrenomyeloneuropathy AMN and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin and Pet Pain Away.

 

 

 

Current Management

  • Rik J Deitsch / President, CEO, CFO
    • Rik J. Deitsch has been the President, Chief Executive Officer and a Director of the Company since November , . From February through November , Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from Cone Snail venom, Cobra venom and Gila Monster venom. Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch has served as an adjunct professor and taught several courses for Florida Atlantic University s College of Business and Continuing Education Department. He is the author of two books: Are You AgeWise A Guide to Healthy Aging, and Invisible Killers the Truth Behind Environmental Genocide.
  • Dale Vanderputten / Chief Scientific Officer
  • Nina Goldstein / IR
  • Rik J Deitsch / Chairman
    • Rik J. Deitsch has been the President, Chief Executive Officer and a Director of the Company since November , . From February through November , Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from Cone Snail venom, Cobra venom and Gila Monster venom. Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch has served as an adjunct professor and taught several courses for Florida Atlantic University s College of Business and Continuing Education Department. He is the author of two books: Are You AgeWise A Guide to Healthy Aging, and Invisible Killers the Truth Behind Environmental Genocide.
  • Stewart Lonky /
  • Garry Pottruck /
  • Harold Rumph /

Current Share Structure

  • Market Cap: $3,726,835 - 03/15/2018
  • Authorized: 2,000,000,000 - 04/17/2017
  • Issue and Outstanding: 1,863,417,568 - 11/20/2017
  • Float: 1,469,627,212 - 09/29/2017

 


Recent Filings from (OTC: NPHC)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: March, 20 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 05 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: NPHC)

Daily Technical Chart for (OTC: NPHC)


Stay tuned for daily updates and more on (OTC: NPHC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: NPHC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NPHC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NPHC and does not buy, sell, or trade any shares of NPHC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/